Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 77, Issue 9, Pages 1295-1302
Publisher
BMJ
Online
2018-08-10
DOI
10.1136/annrheumdis-2018-213328
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
- (2017) Brian G Feagan et al. LANCET
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis
- (2016) Eric Gracey et al. ANNALS OF THE RHEUMATIC DISEASES
- Targeting the interleukin-23/17 axis in axial spondyloarthritis
- (2016) Ananta Paine et al. CURRENT OPINION IN RHEUMATOLOGY
- Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study
- (2015) Xenofon Baraliakos et al. ANNALS OF THE RHEUMATIC DISEASES
- Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
- (2015) James G. Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody
- (2015) Sanjaya Singh et al. mAbs
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
- (2015) Dominique Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
- (2015) Michael M. Ward et al. Arthritis & Rheumatology
- Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
- (2014) Denis Poddubnyy et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-23 Mediates the Intestinal Response to Microbial β-1,3-Glucan and the Development of Spondyloarthritis Pathology in SKG Mice
- (2014) Helen Benham et al. Arthritis & Rheumatology
- In Situ Analysis of Interleukin-23- and Interleukin-12-Positive Cells in the Spine of Patients With Ankylosing Spondylitis
- (2013) Heiner Appel et al. ARTHRITIS AND RHEUMATISM
- Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
- (2013) Dominique Baeten et al. LANCET
- IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells
- (2012) Jonathan P Sherlock et al. NATURE MEDICINE
- Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response
- (2011) Ling Zeng et al. ARTHRITIS AND RHEUMATISM
- Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis
- (2011) Tony J. Kenna et al. ARTHRITIS AND RHEUMATISM
- Spondyloarthritis
- (2011) Maxime Dougados et al. LANCET
- Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses
- (2011) R. Sarin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores
- (2010) P. Machado et al. ANNALS OF THE RHEUMATIC DISEASES
- Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci
- (2010) John D Reveille et al. NATURE GENETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search